- Home
- CRGX vs LDI Comparison
CRGX vs LDI Comparison
Compare CRGX & LDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- LDI
- Stock Information
- Founded
- CRGX 2021
- LDI 2010
- Country
- CRGX United States
- LDI United States
- Employees
- CRGX N/A
- LDI N/A
- Industry
- CRGX
- LDI Finance: Consumer Services
- Sector
- CRGX
- LDI Finance
- Exchange
- CRGX Nasdaq
- LDI Nasdaq
- Market Cap
- CRGX 190.0M
- LDI 221.2M
- IPO Year
- CRGX 2023
- LDI 2021
- Fundamental
- Price
- CRGX $4.25
- LDI $1.31
- Analyst Decision
- CRGX Hold
- LDI Sell
- Analyst Count
- CRGX 7
- LDI 3
- Target Price
- CRGX $4.67
- LDI $1.98
- AVG Volume (30 Days)
- CRGX 569.8K
- LDI 735.5K
- Earning Date
- CRGX 05-08-2025
- LDI 05-06-2025
- Dividend Yield
- CRGX N/A
- LDI N/A
- EPS Growth
- CRGX N/A
- LDI N/A
- EPS
- CRGX N/A
- LDI N/A
- Revenue
- CRGX N/A
- LDI $1,090,719,000.00
- Revenue This Year
- CRGX $58.18
- LDI $28.75
- Revenue Next Year
- CRGX N/A
- LDI $15.05
- P/E Ratio
- CRGX N/A
- LDI N/A
- Revenue Growth
- CRGX N/A
- LDI 21.07
- 52 Week Low
- CRGX $3.00
- LDI $1.01
- 52 Week High
- CRGX $25.45
- LDI $3.23
- Technical
- Relative Strength Index (RSI)
- CRGX 53.57
- LDI 60.49
- Support Level
- CRGX $3.78
- LDI $1.18
- Resistance Level
- CRGX $4.27
- LDI $1.36
- Average True Range (ATR)
- CRGX 0.18
- LDI 0.08
- MACD
- CRGX 0.03
- LDI 0.02
- Stochastic Oscillator
- CRGX 88.79
- LDI 81.48
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.